Stifel stays Buy on Palvella: multiple 'pipeline-in-a-product' opportunities
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $250.00 price target on Palvella Therapeutics (NASDAQ: PVLA)The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
